Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), LeonaBio (LONA) and Solid Biosciences (SLDB)
Analysts from Piper Sandler and Cantor Fitzgerald maintained Buy ratings on NeoGenomics (NEO), LeonaBio (LONA), and Solid Biosciences (SLDB). NeoGenomics has a $21.00 target, LeonaBio a $20.00 target, and Solid Biosciences a $26.00 target. Consensus ratings are Moderate Buy for NEO and Strong Buy for LONA and SLDB, with respective average targets of $18.33, $17.33, and $19.17.
How this was made
The 30-second read
Why it matters
Price target revisions provide modest upside cues but lack rating changes, limiting immediate trading urgency.
Market read
Analyst target updates may influence niche biotech investors but are unlikely to drive broad market moves.
What to watch
Potential regulatory or clinical trial setbacks not addressed.
Background
Analyst coverage updates for three small‑cap biotech firms.
Ticker impact
Piper Sandler analyst maintained a Buy rating on NeoGenomics and set a new price target of $21.00.
Potential modest price appreciation if market follows target.
Target implies ~21% upside from current price; no rating change reduces urgency.
Piper Sandler analyst maintained a Buy rating on LeonaBio with a price target of $20.00.
Possible price rise toward target if investors act on the target.
Target suggests ~156% upside; however, rating unchanged limits immediate impact.
Cantor Fitzgerald analyst maintained a Buy rating on Solid Biosciences and set a price target of $26.00.
Potential upside if market aligns with target expectations.
Target reflects ~168% upside; lack of rating change suggests limited short‑term catalyst.
Market effects
Reinforces bullish sentiment in niche biotech sector.
Limited to U.S. biotech investors.
Minimal global impact beyond sector.
Counterpoint
Analyst targets may be overly optimistic given recent sector volatility.
Key entities
- companyNeoGenomics
US‑listed biotech firm.
- companyLeonaBio
US‑listed biotech firm.
- companySolid Biosciences
US‑listed biotech firm.
